{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:54:38Z","timestamp":1793073278277,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TR000004"],"award-info":[{"award-number":["TR000004"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ymgme.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T12:49:45Z","timestamp":1518439785000},"page":"488-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease"],"prefix":"10.1016","volume":"123","author":[{"given":"Paul","family":"Harmatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mislen","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-9921","authenticated-orcid":false,"given":"Emil","family":"Kakkis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2018.02.006_bb0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0010","article-title":"Prevalence and Incidence of Rare Diseases: Bibliographic Data","author":"Orphanet","year":"2016"},{"key":"10.1016\/j.ymgme.2018.02.006_bb0015","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1172\/JCI1773","article-title":"Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function","volume":"101","author":"O'Connor","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0020","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1172\/JCI117237","article-title":"Enzyme replacement therapy for murine mucopolysaccharidosis type VII","volume":"93","author":"Sands","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0025","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI119322","article-title":"Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation","volume":"99","author":"Sands","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0030","doi-asserted-by":"crossref","first-page":"43160","DOI":"10.1074\/jbc.M107778200","article-title":"Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII","volume":"276","author":"Sands","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0035","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1073\/pnas.0506892102","article-title":"Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII","volume":"102","author":"Vogler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0040","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","article-title":"Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival","volume":"39","author":"Vogler","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0050","first-page":"459","article-title":"A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase","volume":"3","author":"El Dib","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.ymgme.2018.02.006_bb0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0065","series-title":"Prescribing Information","year":"2013"},{"key":"10.1016\/j.ymgme.2018.02.006_bb0070","series-title":"Prescribing Information","year":"2013"},{"key":"10.1016\/j.ymgme.2018.02.006_bb0075","series-title":"Prescribing Information","year":"2013"},{"key":"10.1016\/j.ymgme.2018.02.006_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2014.09.009","article-title":"A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses","volume":"114","author":"Zhang","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"American Thoracic Society\/European Respiratory Society statement on respiratory muscle testing","volume":"166","author":"ATS\/ERS","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2018.02.006_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","volume":"117","author":"Arch-Ophthalmol","year":"1999","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1475-1313.1993.tb00421.x","article-title":"Reliability of high- and low-contrast letter charts","volume":"13","author":"Reeves","year":"1993","journal-title":"Ophthalmic Physiol. Opt."},{"key":"10.1016\/j.ymgme.2018.02.006_bb0115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ridd.2009.03.003","article-title":"Rasch analysis of the Bruininks-Oseretsky test of motor proficiency-second edition in intellectual disabilities","volume":"30","author":"Wuang","year":"2009","journal-title":"Res. Dev. Disabil."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217307369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217307369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T03:37:15Z","timestamp":1565321835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217307369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1096719217307369"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Ultragenyx Pharmaceutical Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}